Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Exp Med. Sep 20, 2025; 15(3): 107020
Published online Sep 20, 2025. doi: 10.5493/wjem.v15.i3.107020
Published online Sep 20, 2025. doi: 10.5493/wjem.v15.i3.107020
Glucagon-like peptide and its receptor agonists for the treatment of rheumatic diseases
Elie Chamchoum, Nadia Katrib, Nicolas Nassif, Yara Ratel, Faculty of Medicine and Medical Sciences, University of Balamand, Beirut 1, Lebanon
Mohamad Ali Rida, Department of Internal Medicine, Clemenceau Medical Center, Beirut 1, Lebanon
Author contributions: Chamchoum E, Katrib N, Nassif N, and Ratel Y contributed to the manuscript writing, literature review, and table making; Rida MA contributed to the manuscript writing, review, and correction.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mohamad Ali Rida, MD, Assistant Professor, Department of Internal Medicine, Clemenceau Medical Center, Clemenceau, Beirut 1, Lebanon.
Received: March 13, 2025
Revised: May 10, 2025
Accepted: July 10, 2025
Published online: September 20, 2025
Processing time: 152 Days and 11.9 Hours
Revised: May 10, 2025
Accepted: July 10, 2025
Published online: September 20, 2025
Processing time: 152 Days and 11.9 Hours
Core Tip
Core Tip: Growing evidence suggests that glucagon-like peptide-1 and its receptor agonists could be an effective treatment option not only for metabolic disorders but also for a range of autoimmune and inflammatory diseases. They may protect cartilage and reduce joint inflammation, lower the levels of inflammatory cytokines, and help prevent further joint damage and address both the metabolic and inflammatory aspects, reducing cytokine levels and potentially improving disease outcomes.